%0 Journal Article
%A Schlenk, Richard
%A Stegelmann, F.
%A Reiter, A.
%A Jost, E.
%A Gattermann, N.
%A Hebart, H.
%A Waller, C.
%A Hochhaus, A.
%A Platzbecker, U.
%A Schafhausen, P.
%A Blau, I. W.
%A Verbeek, W.
%A Heidel, F. H.
%A Werner, M.
%A Kreipe, H.
%A Teleanu, V.
%A Benner, A.
%A Döhner, H.
%A Grießhammer, M.
%A Döhner, K.
%T Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
%J Leukemia
%V 31
%N 4
%@ 1476-5551
%C Basingstoke
%I Nature Publ. Group
%M DKFZ-2017-00130
%P 889-895
%D 2017
%X Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27774990
%R 10.1038/leu.2016.299
%U https://inrepo02.dkfz.de/record/119376